Esber Zahia, Schwarze Eric, Critchfield Jeffery, Soubani Ayman O
Wayne State University School of Medicine, Division of Pulmonary and Critical Care Medicine, USA.
Wayne State University, School of Medicine, USA.
Respir Med Case Rep. 2019 Aug 3;28:100920. doi: 10.1016/j.rmcr.2019.100920. eCollection 2019.
Hemangiopericytomas (HPC) are perivascular neoplasms that are rarely encountered as primary lung malignancy. Surgical resection remains the mainstay therapy of HPC. A 37-year old African American female initially presented with fatigue, chest pain and palpitations. Chest radiography showed a well-circumscribed large heterogeneous vascular mass of the right hemithorax. She underwent a CT-guided biopsy of the thoracic mass and was diagnosed with low-grade pulmonary hemangiopericytoma. High tumor vascularity burden and liver metastases precluded her from being a surgical candidate. Three years ago, she referred to our facility seeking further management. She did not tolerate systemic chemotherapy. Alternatively, she had been successfully managed with serial transarterial embolization and oral angiogenesis inhibitor to date. This therapeutic approach can be further explored for long term control of unresectable pulmonary HPC.
血管外皮细胞瘤（HPC）是一种血管周围肿瘤，作为原发性肺恶性肿瘤很少见。手术切除仍然是HPC的主要治疗方法。一名37岁的非裔美国女性最初表现为疲劳、胸痛和心悸。胸部X线检查显示右半胸有一个边界清楚的大的异质性血管肿块。她接受了胸部肿块的CT引导下活检，被诊断为低级别肺血管外皮细胞瘤。高肿瘤血管负荷和肝转移使她不适合手术。三年前，她转诊到我们机构寻求进一步治疗。她无法耐受全身化疗。到目前为止，她通过连续经动脉栓塞和口服血管生成抑制剂成功得到治疗。这种治疗方法可进一步探索用于不可切除肺HPC的长期控制。
